Dr. Francis Bullock is a Senior Advisor to PureTech Ventures. Previously, he served as the Senior Vice President, Research Operations at Schering Plough Research Institute, from 1981-1993, where he took over 30 new chemical entities into clinical development in many therapeutic areas including antibacterials, antifungals, antivirals, cardiovasculars, pain, inflammation, allergy, and cancer.
His track record includes five successful registrations including Claritin and Intron (Interferon Alpha 2b) that generated cumulative peak sales of around $3.5B annually.
Dr. Bullock serves on the board of directors for TSI Corporation, GTC Biotherapeutics, Array Biopharma, and ARCA Discovery.